Results 231 to 240 of about 101,548 (353)

Endogenous GIP signaling is indispensable for DPP‐4 inhibitor‐mediated metabolic control in mice

Journal of Diabetes Investigation, EarlyView.
This study reveals that the metabolic benefits of DPP‐4 inhibitors, including improved glucose tolerance and reduced body weight, are completely abolished in GIP receptor‐deficient mice. These findings establish that endogenous GIP signaling, rather than GLP‐1, is the indispensable key player for the efficacy of this drug class.
Saki Kubota‐Okamoto, Sodai Kubota, Hiromi Tsuchida, Yanyan Liu, Seiya Banno, Toshinori Imaizumi, Taro Fujisawa, Yoshihiro Takahashi, Takehiro Kato, Yukio Horikawa, Katsumi Iizuka, Takaaki Murakami, Yuuka Fujiwara, Hitoshi Kuwata, Yuji Yamazaki, Yutaka Seino, Shin Tsunekawa, Daisuke Yabe   +17 more
wiley   +1 more source

Patterns and costs associated with glucagon-like peptide-1 receptor agonist use in US adults with type 2 diabetes. [PDF]

J Manag Care Spec Pharm
Wu J, Perez A, Sullivan PW.
europepmc   +1 more source

Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY)

Journal of Diabetes Investigation, EarlyView.
To investigate the safety of anagliptin/metformin combination tablets in Japanese patients of type 2 diabetes with moderate renal impairment. This study demonstrates that the fixed‐dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction.
Hiroshi Kajio, Ryotaro Bouchi, Mitsuhisa Komatsu, Masanori Yamazaki, Daisuke Takarabe, Masahide Okamoto, Takahisa Tanaka, Toru Kitazawa, Hisayuki Katsuyama, Yasumichi Mori, Mitsuhiko Noda   +10 more
wiley   +1 more source

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use

Indian Journal of Endocrinology and Metabolism, 2015
Sanjay Kalra, Mallya Ganapathi, Ambrish Mithal   +2 more
doaj   +1 more source

Severe reflux oesophagitis caused by repeated vomiting due to glucagon-like peptide-1 receptor agonist. [PDF]

BMJ Case Rep
Kashima S, Moriichi K, Fujiya M.
europepmc   +1 more source

Hyperdilute Radiesse Preserves Facial Volume in Glucagon-Like Peptide-1 Receptor Agonist Users Undergoing Rapid Weight Loss. [PDF]

Aesthet Surg J Open Forum
Durairaj KK, McCarthy AD, Yambao M, Linnemann-Heath J.   +3 more
europepmc   +1 more source

Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report. [PDF]

Am J Case Rep
Itsathitpaisarn R, Suksawad N, Wongwikrom W, Surintrspanont J, Thongsricome T.   +4 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

Diabetologia, 2011
Ryo Kodera, K. Shikata, Hitomi Kataoka, Tetsuharu Takatsuka, S. Miyamoto, Motofumi Sasaki, Nobuo Kajitani, Shingo Nishishita, Kei Sarai, Daisho Hirota, Chikage Sato, D. Ogawa, Hirofumi Makino   +12 more
semanticscholar   +1 more source

Impact of weight‐loss interventions on psoriasis severity: A systematic review and meta‐analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Weight‐loss interventions were associated with clinically and statistically significant improvements in psoriasis severity (PASI and PASI 75) and quality of life (DLQI). These findings support the role of weight‐loss interventions as effective adjuncts to medical therapy and their integration into holistic psoriasis care.
Sarah Morrow, Poppy Hawkins, Christopher E. M. Griffiths, Thanasis G. Tektonidis, Eli Harriss, Jadine Scragg, Susan Jebb   +6 more
wiley   +1 more source

Unanticipated Residual Gastric Contents in an Appropriately Fasted Pediatric Patient on Glucagon-Like Peptide-1 Receptor Agonist Therapy: A Case Report and Review of Perioperative Considerations. [PDF]

Cureus
Lookabaugh M, Strupp KM, Webb L.
europepmc   +1 more source